A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

European Neurology

Volumn 44, Issue 4, 2000, Pages 236-241

  Farlow, Martin ^a   Anand, Ravi ^b   Messina Jr , John ^b   Hartman, Richard ^b   Veach, Jeffrey ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Clinical trial; Rivastigmine

Indexed keywords

RIVASTIGMINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033679259     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008243     Document Type: Article

References (10)

1. Observations and suggestions on anti-dementia drug development
2. Slowing the progression of Alzheimer disease: Methodologic issues
3. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
4. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
5. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
6. Efficacy safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
7. A new rating scale for Alzheimer's disease
8. Cholinergic markers in elderly patients with early signs of Alzheimer disease
9. Clinical predictors of course of Alzheimer patients in a longitudinal study: A preliminary report
10. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration